<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4735780</article-id><article-id pub-id-type="doi">10.1002/cam4.595</article-id><article-id pub-id-type="publisher-id">CAM4595</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Cancer Research</subject><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="35804" pm="."><plain>Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib id="cam4595-cr-0001" contrib-type="author"><name><surname>Koole</surname><given-names>Koos</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="cam4595-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cam4595-cr-0002" contrib-type="author"><name><surname>van Kempen</surname><given-names>Pauline M. W.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cam4595-cr-0003" contrib-type="author"><name><surname>Swartz</surname><given-names>Justin E.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cam4595-cr-0004" contrib-type="author"><name><surname>Peeters</surname><given-names>Ton</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam4595-cr-0005" contrib-type="author"><name><surname>van Diest</surname><given-names>Paul J.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam4595-cr-0006" contrib-type="author"><name><surname>Koole</surname><given-names>Ron</given-names></name><xref ref-type="aff" rid="cam4595-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cam4595-cr-0007" contrib-type="author"><name><surname>van Es</surname><given-names>Robert J. J.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cam4595-cr-0008" contrib-type="author" corresp="yes"><name><surname>Willems</surname><given-names>Stefan M.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="cam4595-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="cam4595-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Pathology</named-content><institution>University Medical Center Utrecht</institution><named-content content-type="street">Heidelberglaan 100</named-content><named-content content-type="country-part">3584 CX</named-content><named-content content-type="city">Utrecht</named-content><country country="NL">The Netherlands</country></aff><aff id="cam4595-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Head and Neck Surgical Oncology</named-content><named-content content-type="organisation-division">UMC Utrecht Cancer Center</named-content><institution>University Medical Center Utrecht</institution><named-content content-type="street">Heidelberglaan 100</named-content><named-content content-type="post-code">3584 CX</named-content><named-content content-type="city">Utrecht</named-content><country country="NL">The Netherlands</country></aff><aff id="cam4595-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Otorhinolaryngology – Head and Neck Surgery</named-content><institution>University Medical Center Utrecht</institution><named-content content-type="street">Heidelberglaan 100</named-content><named-content content-type="post-code">3584 CX</named-content><named-content content-type="city">Utrecht</named-content><country country="NL">The Netherlands</country></aff><aff id="cam4595-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Molecular Carcinogenesis</named-content><institution>Netherlands Cancer Institute</institution><named-content content-type="street">Plesmanlaan 121</named-content><named-content content-type="post-code">1066 CX</named-content><named-content content-type="city">Amsterdam</named-content><country country="NL">The Netherlands</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Stefan Willems, Department of Pathology<bold>,</bold> University Medical Center Utrecht, H4.2.41<bold>,</bold> Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel: +31 (0) 88 755 6568; Fax: +31 (0) 88 756 9593; E‐mail: <email>s.m.willems-4@umcutrecht.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2016</year></pub-date><volume>5</volume><issue>2</issue><issue-id pub-id-type="doi">10.1002/cam4.2016.5.issue-2</issue-id><fpage>275</fpage><lpage>284</lpage><history><date date-type="received"><day>07</day><month>8</month><year>2015</year></date><date date-type="rev-recd"><day>06</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2015 The Authors. <italic>Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAM4-5-275.pdf"/><abstract abstract-type="main" id="cam4595-abs-0001"><title><text><SENT sid="35805" pm="."><plain>Abstract </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="35806" pm="."><plain>Fibroblast growth factor receptor 3 (FGFR3) is a member of the fibroblast growth factor receptor tyrosine kinase family. </plain></SENT>
<SENT sid="35807" pm="."><plain>It has been identified as a promising therapeutic target in multiple types of cancer. </plain></SENT>
<SENT sid="35808" pm="."><plain>We have investigated FGFR3 protein expression and FGFR3 gene copy‐numbers in a single well‐documented cohort of oral and oropharyngeal squamous cell carcinoma. </plain></SENT>
<SENT sid="35809" pm="."><plain>Tissue microarray sets containing 452 formalin‐fixed paraffin‐embedded tissues were immunohistochemically stained with an anti‐FGFR3 antibody and hybridized with a FGFR3 fluorescence in situ hybridization probe. FGFR3 protein expression was correlated with clinicopathological and survival data, which were retrieved from electronic medical records. FGFR3 mRNA data of 522 head and neck squamous cell carcinoma (HNSCC) were retrieved from The Cancer Genome Atlas (TCGA). </plain></SENT>
<SENT sid="35810" pm="."><plain>Fibroblast growth factor receptor 3 (FGFR3) protein was overexpressed in 48% (89/185) of oral and 59% (124/211) of oropharyngeal squamous cell carcinoma. </plain></SENT>
<SENT sid="35811" pm="."><plain>Overexpression of FGFR3 protein was not related to overall survival or disease‐free survival in oral (HR[hazard ratio]: 0.94; 95% CI: 0.64–1.39; P = 0.77, HR: 0.94; 95% CI: 0.65–1.36; P = 0.75) and oropharyngeal squamous cell carcinoma (HR: 1.21; 95% CI: 0.81–1.80; P = 0.36, HR: 0.42; 95% CI: 0.79–1.77; P = 0.42). FGFR3 mRNA was upregulated in 3% (18/522) of HNSCC from the TCGA. </plain></SENT>
<SENT sid="35812" pm="."><plain>The FGFR3 gene was gained in 0.6% (1/179) of oral squamous cell carcinoma but no amplification was found in oral and oropharyngeal squamous cell carcinoma. </plain></SENT>
<SENT sid="35813" pm="."><plain>In conclusion, FGFR3 protein is frequently overexpressed in oral and oropharyngeal squamous cell carcinoma. </plain></SENT>
<SENT sid="35814" pm="."><plain>Therefore, it may serve as a potential therapeutic target for FGFR3‐directed therapies in oral and oropharyngeal squamous cell carcinoma. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author-generated"><kwd id="cam4595-kwd-0001">fibroblast growth factor receptor 3</kwd><kwd id="cam4595-kwd-0002">oral cancer</kwd><kwd id="cam4595-kwd-0003">oropharyngeal cancer</kwd><kwd id="cam4595-kwd-0004">therapeutic target</kwd></kwd-group></SecTag><funding-group><award-group><funding-source>Dutch Cancer Society</funding-source><award-id>2011–4964</award-id></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cam4595</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.6 mode:remove_FC converted:02.02.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cam4595-cit-1001">
<source>Cancer Medicine</source>
<year>2016</year>; <volume>5</volume>(<issue>2</issue>): <fpage>275</fpage>–<lpage>284</lpage>
</mixed-citation>
</p></notes></front><body><SecTag type="INTRO"><sec id="cam4595-sec-0001"><title><text><SENT sid="35815" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="35816" pm="."><plain>Fibroblast growth factor receptor 3 (FGFR3) is a cell membrane‐bound tyrosine kinase receptor belonging to the fibroblast growth factor receptor family (FGFR1‐4) 1. </plain></SENT>
<SENT sid="35817" pm="."><plain>Upon binding of specific FGF ligands, the receptor is phosphorylated and multiple downstream signaling pathways are activated. </plain></SENT>
<SENT sid="35818" pm="."><plain>Among these pathways are the mitogen‐activated protein kinase (MAPK), (phosphoinositide 3‐kinase/protein kinase B (PI3K/AKT), phosphoinositide phospholipase C (PLCγ) and signal transducer and activator of transcription (STAT) signaling pathways 2. </plain></SENT>
<SENT sid="35819" pm="."><plain>Activation of these pathways leads to cell proliferation, migration, invasion, cell survival, and angiogenesis. </plain></SENT>
<SENT sid="35820" pm="."><plain>In cancer, oncogenic aberrations of the FGFR3 gene cause sustained cell proliferation, contributing to tumor development 3. </plain></SENT>
<SENT sid="35821" pm="."><plain>Genomic aberrations include FGFR3 driver mutations, FGFR3 gene amplification, and FGFR3 translocations, which frequently occur in bladder cancer, myeloma, and glioblastoma 4, 5. </plain></SENT>
<SENT sid="35822" pm="."><plain>Due to its contribution to tumor development, FGFR3 is an interesting therapeutic target and targeted therapies aimed at FGFR3 are emerging. </plain></SENT>
<SENT sid="35823" pm="."><plain>Inhibiting FGFR3 protein with FGFR3‐directed therapies caused remarkable antitumor effects in preclinical models on brain cancer, colorectal cancer, and multiple myeloma, as well as in clinical trials on glioblastoma patients with tumors bearing FGFR3‐TACC3 fusions 3, 4, 6. </plain></SENT>
<SENT sid="35824" pm="."><plain>At the moment, early phase clinical trials are conducted with FGFR3‐directed targeted therapies on patients with FGFR3‐aberrated glioblastoma multiforme, transitional cell carcinoma, multiple myeloma, and other advanced solid malignancies (ClinicalTrials.gov Identifier: NCT01975701, NCT02278978, NCT02401542, NCT02052778). </plain></SENT>
</text></p><p><text><SENT sid="35825" pm="."><plain>For head and neck squamous cell carcinoma (HNSCC), the knowledge on FGFR3 protein expression is yet limited, while such novel therapeutic targets are highly awaited for disseminated or recurrent HNSCC because current treatment regimens are often ineffective and overall survival rates have remained poor over the past two decades 7, 8. </plain></SENT>
<SENT sid="35826" pm="."><plain>In this study, we therefore investigated FGFR3 protein expression and its relation to overall survival, disease‐free survival, and regional lymph node metastases in well‐documented cohorts of oral and oropharyngeal squamous cell carcinoma (OSCC, OPSCC). </plain></SENT>
<SENT sid="35827" pm="."><plain>Second, we investigated FGFR3 gene copy‐numbers in these OSCC and OPSCC cohorts. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="cam4595-sec-0002"><title><text><SENT sid="35828" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="cam4595-sec-0003"><title><text><SENT sid="35829" pm="."><plain>Patient cohort </plain></SENT>
</text></title><p><text><SENT sid="35830" pm="."><plain>The inclusion criteria were as follows: patients with a first primary OPSCC or OSCC who were treated at the University Medical Center Utrecht (UMC Utrecht) between August 1996 and December 2011. </plain></SENT>
<SENT sid="35831" pm="."><plain>The exclusion criteria were as follows: a previous history of HNSCC, a synchronous primary tumor, histologic abnormalities including inflammation and dysplastic lesions, and the absence of tumor cores on tissue microarray (TMA) slides. </plain></SENT>
<SENT sid="35832" pm="."><plain>The patient cohort included 212 OSCC and 240 OPSCC patients. </plain></SENT>
<SENT sid="35833" pm="."><plain>TMA cores were absent for 27 OSCC and 29 OPSCC, leaving 185 OSCC and 211 OPSCC for analysis of FGFR3 protein expression. </plain></SENT>
<SENT sid="35834" pm="."><plain>OSCC and OPSCC patients were treated according to the Dutch National Guideline for Head and Neck Cancer 2014 9. </plain></SENT>
<SENT sid="35835" pm="."><plain>The treatment regimen of OSCC consisted of primary surgical resection and an additional neck dissection and/or postoperative radiotherapy or chemoradiotherapy if recommended. </plain></SENT>
<SENT sid="35836" pm="."><plain>The treatment regimen of OPSCC consisted of primary surgery, radiotherapy, or chemoradiotherapy and an additional neck dissection or postoperative radiotherapy or chemoradiotherapy if recommended. </plain></SENT>
<SENT sid="35837" pm="."><plain>For OSCC patients, the median follow‐up of overall survival was 90.5 months and of disease‐free survival was 91.5 months. </plain></SENT>
<SENT sid="35838" pm="."><plain>For OPSCC patients, the median follow‐up time of overall survival was 71 months and of disease‐free survival was 63 months. </plain></SENT>
<SENT sid="35839" pm="."><plain>Clinicopathological patient and tumor characteristics were retrieved from electronic medical records and formalin‐fixed paraffin‐embedded tissues of all tumors were collected. </plain></SENT>
<SENT sid="35840" pm="."><plain>Oral squamous cell carcinoma (OSCC) tissues were surgical resection specimens as surgery was the standard treatment regimen for OSCC, and OPSCC tissues were mainly pretreatment biopsy specimens as chemoirradiation was the treatment regimen for the majority of OPSCC. </plain></SENT>
<SENT sid="35841" pm="."><plain>Since limited OPSCC resection specimens were available for microscopic analysis by a pathologist, pathological characteristics of these tumors were not available. </plain></SENT>
<SENT sid="35842" pm="."><plain>The Human Papillomavirus (HPV) status of all tumors was determined by P16 immunohistochemistry and linear array, as described previously 10. “The code for proper secondary use of human tissue” and “The code of conduct for the use of data in health research” of the Federation of Dutch Medical Scientific Societies were followed when handling human tissues and patient data (Federa FMVV, updated 2011). </plain></SENT>
</text></p></sec><sec id="cam4595-sec-0004"><title><text><SENT sid="35843" pm="."><plain>Tissue microarray construction </plain></SENT>
</text></title><p><text><SENT sid="35844" pm="."><plain>Slides (4 μm) cut from formalin‐fixed paraffin‐embedded (FFPE) tissue blocks were hematoxylin stained and tumor areas were marked by a dedicated head and neck pathologist (SMW). </plain></SENT>
<SENT sid="35845" pm="."><plain>Three 0.6 mm cores were punched from marked tumor areas of each FFPE tissue block and these were arrayed into recipient paraffin donor blocks using a TMA Grand Master (3DHISTECH, Budapest, Hungary). </plain></SENT>
<SENT sid="35846" pm="."><plain>Six normal oral and tonsillar tissue TMA cores were arrayed in each TMA and served as staining quality controls. </plain></SENT>
</text></p></sec><sec id="cam4595-sec-0005"><title><text><SENT sid="35847" pm="."><plain>Immunohistochemistry </plain></SENT>
</text></title><p><text><SENT sid="35848" pm="."><plain>Tissue microarray (TMA) slides were immunohistochemically stained using a mouse monoclonal anti‐FGFR3 (B‐9) SC‐13121 antibody (Santa Cruz Biotechnology, Dallas, TX). </plain></SENT>
<SENT sid="35849" pm="."><plain>The anti‐FGFR3 antibody was tested for the following tissue pretreatments; EDTA, citrate, pepsine and no treatment, and the following antibody dilutions; 1:10, 1:25, 1:50, 1:100, 1:250, 1:500, and 1:1000 on a positive control (normal liver tissue) and negative control (normal stomach tissue) to verify the antibody's specificity for FGFR3 protein 11. </plain></SENT>
<SENT sid="35850" pm="."><plain>Tissue pretreatment with EDTA and a 1:25 antibody dilution showed the most specific staining. </plain></SENT>
<SENT sid="35851" pm="."><plain>The following manual staining protocol was used; first, TMA slides were deparaffinized and treated with peroxidase inhibitor for 15 min, followed by an EDTA pretreatment step at 100°C for 20 min. </plain></SENT>
<SENT sid="35852" pm="."><plain>After rinsing in demineralized water and PBS tween, slides were incubated with primary anti‐FGFR3 antibody at 1:25 dilution for one hour and rinsed in PBS sequenza. </plain></SENT>
<SENT sid="35853" pm="."><plain>Next, slides were incubated with 150 μL poly‐HRP‐anti‐mouse/rabbit/rat IgG secondary antibody (Immunologic, Duiven, The Netherlands) for 30 min, followed by rinsing in PBS sequenza and citrate buffer. </plain></SENT>
<SENT sid="35854" pm="."><plain>200 μL 3,3’‐diaminobenzidine (DAB) was applied for 10 min and slides were rinsed in citrate buffer. </plain></SENT>
<SENT sid="35855" pm="."><plain>Finally, slides were counterstained with hematoxylin, dehydrated, and covered. </plain></SENT>
</text></p><p><text><SENT sid="35856" pm="."><plain>To quantify FGFR3 protein expression, the resultant immunohistochemical stain was scored in a semiquantitative manner by two observers (S. </plain></SENT>
<SENT sid="35857" pm="."><plain>M. </plain></SENT>
<SENT sid="35858" pm="."><plain>W and K. K) blinded to patient's outcome. </plain></SENT>
<SENT sid="35860" pm="."><plain>The percentage of positively stained tumor cells was scored and the mean tumor cell percentage was computed from available TMA cores for each tumor. </plain></SENT>
<SENT sid="35861" pm="."><plain>Seventy‐four tumors included in the analysis had only one TMA core available and 138 tumors had only two. </plain></SENT>
<SENT sid="35862" pm="."><plain>Continuous tumor cell percentage scores were dichotomized by a cut‐off value, which was optimized to best predicting patient overall survival using log‐likelihood values 12. </plain></SENT>
<SENT sid="35863" pm="."><plain>A cut‐off value of 33% was selected for both OSCC and OPSCC. </plain></SENT>
<SENT sid="35864" pm="."><plain>The staining intensity was not scored because it was homogenous among all TMA cores. </plain></SENT>
</text></p></sec><sec id="cam4595-sec-0006"><title><text><SENT sid="35865" pm="."><plain>Fluorescence in situ hybridization </plain></SENT>
</text></title><p><text><SENT sid="35866" pm="."><plain>Tissue microarrays were hybridized with an IGH/FGFR3 (IGH, immunoglobulin heavy locus) translocation dual fusion FISH (fluorescence in situ hybridization) probe (Cytocell, Cambridge, UK). </plain></SENT>
<SENT sid="35867" pm="."><plain>In brief, 4 μm TMA slides were deparaffinized, rinsed in HCL solution, and pretreated with citrate and protease buffer. </plain></SENT>
<SENT sid="35868" pm="."><plain>Next, these slides were dehydrated, and incubated with 15 μL Fluorescence in situ hybridization (FISH) probe for 5 min at 78°C. </plain></SENT>
<SENT sid="35869" pm="."><plain>After cooling samples for 5 min, TMA slides were incubated overnight at 37°C in a Thermobrite (Abbott Laboratories, Abbott Park, IL). </plain></SENT>
<SENT sid="35870" pm="."><plain>The next day, TMA slides were rinsed in specific saline‐sodium citrate buffers and counterstained with 4’,6‐diamidino‐2‐phenylindole (DAPI). </plain></SENT>
<SENT sid="35871" pm="."><plain>Finally, slides were dehydrated and 15 μL vectashield was applied. </plain></SENT>
<SENT sid="35872" pm="."><plain>To determine FGFR3 gene copy‐numbers, 50 tumor cell nuclei per tumor were assessed on FGFR3 and IGH gene copy‐numbers at 100× magnification using a Leica DM5500 B microscope system with Leica application suite advanced fluorescence software (Leica Microsystems, Rijswijk, The Netherlands). </plain></SENT>
<SENT sid="35873" pm="."><plain>A FGFR3/IGH ratio was calculated and defined as: &lt;1.5: normal copy‐numbers, 1.5–2.0: copy‐number gain and &gt;2.0: gene amplification 13. </plain></SENT>
</text></p></sec><sec id="cam4595-sec-0007"><title><text><SENT sid="35874" pm="."><plain>TCGA data collection </plain></SENT>
</text></title><p><text><SENT sid="35875" pm="."><plain>FGFR3 mRNA data, available for 522 HNSCC, were retrieved from The Cancer Genome Atlas (TCGA) Research Network (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>). </plain></SENT>
<SENT sid="35876" pm="."><plain>Data were extracted from the TCGA Head and Neck Squamous Cell Carcinoma Provisional study through the cBioPortal for Cancer Genomics website (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/">http://www.cbioportal.org/</ext-link>) on the 29th of September, 2015 14, 15. </plain></SENT>
<SENT sid="35877" pm="."><plain>Upregulated FGFR3 mRNA levels were defined as z‐scores above two standard deviations and downregulated FGFR3 mRNA levels as below two standard deviations from the reference population. </plain></SENT>
<SENT sid="35878" pm="."><plain>No limitations or publication restrictions were laid upon the HNSCC data, as stated by the TCGA publication guidelines. </plain></SENT>
</text></p></sec><sec id="cam4595-sec-0008"><title><text><SENT sid="35879" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="35880" pm="."><plain>Statistical analysis was performed using IBM SPSS Statistics software, version 22 (IBM, Amonk, NY). </plain></SENT>
<SENT sid="35881" pm="."><plain>Pearson's chi square test was used for dichotomous variables or Fisher's exact test for the variables; primary treatment type, neck dissection and HPV status, and t‐test was used for continuous variables to compare baseline characteristics between OSCC and OPSCC. </plain></SENT>
<SENT sid="35882" pm="."><plain>A Pearson's chi square test was used to compare protein expression between OSCC and OPSCC. </plain></SENT>
<SENT sid="35883" pm="."><plain>A Pearson's chi square was also used to analyze univariate associations between FGFR3 protein expression and clinicopathological variables. </plain></SENT>
</text></p><p><text><SENT sid="35884" pm="."><plain>Only patients who were treated with curative intent were included in the survival analysis. </plain></SENT>
<SENT sid="35885" pm="."><plain>The median follow‐up time was estimated using the reverse Kaplan–Meier method. </plain></SENT>
<SENT sid="35886" pm="."><plain>The relation between FGFR3 protein expression and both overall survival and disease‐free survival was analyzed by plotting Kaplan–Meier survival curves and comparing them by log‐rank test. </plain></SENT>
<SENT sid="35887" pm="."><plain>Associations were further analyzed by univariate Cox regression. </plain></SENT>
<SENT sid="35888" pm="."><plain>Two‐sided P‐values below 0.05 were considered significant throughout all statistical computations. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="cam4595-sec-0009"><title><text><SENT sid="35889" pm="."><plain>Results </plain></SENT>
</text></title><sec id="cam4595-sec-0010"><title><text><SENT sid="35890" pm="."><plain>Clinicopathological characteristics </plain></SENT>
</text></title><p><text><SENT sid="35891" pm="."><plain>The OSCC patient cohort included 212 OSCC, of which 30% were early I–II stage tumors and 70% advanced III–IV stage tumors (Table 1). </plain></SENT>
<SENT sid="35892" pm="."><plain>Regarding treatment regimens, all OSCC were primarily treated with surgery (100%) and 97% received a neck dissection. </plain></SENT>
<SENT sid="35893" pm="."><plain>Postoperative radiotherapy was administered to the primary site and/or neck in 34%. </plain></SENT>
<SENT sid="35894" pm="."><plain>The OPSCC patient cohort included 240 OPSCC, of which 15% were early I–II stage tumors and 85% advanced III–IV stage tumors. </plain></SENT>
<SENT sid="35895" pm="."><plain>19% of OPSCC were HPV‐positive and 81% HPV‐negative. </plain></SENT>
<SENT sid="35896" pm="."><plain>HPV status was missing for nine OPSCC. </plain></SENT>
<SENT sid="35897" pm="."><plain>Of all OPSCC's, 77% were treated either primarily or postoperative with chemo‐irradiation or radiotherapy. </plain></SENT>
<SENT sid="35898" pm="."><plain>Twenty‐five percent were primarily treated with surgery. </plain></SENT>
<SENT sid="35899" pm="."><plain>Eleven percent of OPSCC were treated with palliative intent. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="cam4595-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="35900" pm="."><plain>Clinicopathological characteristics of oral and oropharyngeal squamous cell carcinoma cohorts </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="35901" pm="."><plain>Clinicopathological characteristics </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="35902" pm="."><plain>OSCC n (%) </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="35903" pm="."><plain>OPSCC n (%) </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="35904" pm="."><plain>P </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="35905" pm="."><plain>Total number of cases </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35906" pm="."><plain>212 (100) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35907" pm="."><plain>240 (100) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35908" pm="."><plain>Age </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35909" pm="."><plain>Median (range) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35910" pm="."><plain>62 (26–87) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35911" pm="."><plain>59 (35–88) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35912" pm="."><plain>0.005 </plain></SENT>
</text></td></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35913" pm="."><plain>Sex </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35914" pm="."><plain>Male </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35915" pm="."><plain>128 (60) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35916" pm="."><plain>167 (70) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35917" pm="."><plain>0.040 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35918" pm="."><plain>Female </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35919" pm="."><plain>84 (40) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35920" pm="."><plain>73 (30) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35921" pm="."><plain>Tobacco smoking </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35922" pm="."><plain>Never </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35923" pm="."><plain>77 (36) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35924" pm="."><plain>48 (20) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35925" pm="."><plain>0.012 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35926" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35927" pm="."><plain>133 (63) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35928" pm="."><plain>192 (80) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35929" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35930" pm="."><plain>2 (1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35931" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35932" pm="."><plain>Alcohol consumption </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35933" pm="."><plain>Never </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35934" pm="."><plain>102 (48) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35935" pm="."><plain>38 (15.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35936" pm="."><plain>0.008 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35937" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35938" pm="."><plain>108 (51) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35939" pm="."><plain>201 (84) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35940" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35941" pm="."><plain>2 (1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35942" pm="."><plain>1 (0.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35943" pm="."><plain>Clinical T‐stage </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35944" pm="."><plain>cT1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35945" pm="."><plain>44 (21) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35946" pm="."><plain>21 (8.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35947" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35948" pm="."><plain>cT2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35949" pm="."><plain>79 (37) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35950" pm="."><plain>68 (28) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35951" pm="."><plain>cT3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35952" pm="."><plain>19 (9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35953" pm="."><plain>56 (23) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35954" pm="."><plain>cT4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35955" pm="."><plain>70 (33) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35956" pm="."><plain>94 (39) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35957" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35958" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35959" pm="."><plain>1 (0.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35960" pm="."><plain>Clinical N‐stage </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35961" pm="."><plain>cN0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35962" pm="."><plain>146 (69) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35963" pm="."><plain>60 (25) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35964" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35965" pm="."><plain>cN1‐3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35966" pm="."><plain>66 (31) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35967" pm="."><plain>175 (74) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35968" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35969" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35970" pm="."><plain>3 (1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1"><text><SENT sid="35971" pm="."><plain>Pathological N‐stage </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35972" pm="."><plain>pN0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35973" pm="."><plain>91 (43) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35974" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35975" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35976" pm="."><plain>pN1‐3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35977" pm="."><plain>114 (54) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35978" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35979" pm="."><plain>7 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35980" pm="."><plain>Tumor stage </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35981" pm="."><plain>Early I–II </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35982" pm="."><plain>64 (30) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35983" pm="."><plain>36 (15) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35984" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35985" pm="."><plain>Advanced III–IV </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35986" pm="."><plain>148 (70) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35987" pm="."><plain>204 (85) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35988" pm="."><plain>Primary treatment type </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35989" pm="."><plain>Surgery </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35990" pm="."><plain>212 (100) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35991" pm="."><plain>61 (25) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35992" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35993" pm="."><plain>Radiotherapy or chemoradiotherapy </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35994" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35995" pm="."><plain>153 (64) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="35996" pm="."><plain>Palliative </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35997" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="35998" pm="."><plain>26 (11) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="35999" pm="."><plain>Neck dissection </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36000" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36001" pm="."><plain>205 (97) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36002" pm="."><plain>28 (12) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36003" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36004" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36005" pm="."><plain>7 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36006" pm="."><plain>186 (77) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36007" pm="."><plain>Palliative </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36008" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36009" pm="."><plain>26 (11) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36010" pm="."><plain>Postoperative Radiotherapy or chemoradiotherapy </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36011" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36012" pm="."><plain>73 (34) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36013" pm="."><plain>31 (13) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36014" pm="."><plain>0.020 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36015" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36016" pm="."><plain>139 (66) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36017" pm="."><plain>30 (13) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36018" pm="."><plain>Palliative </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36019" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36020" pm="."><plain>26 (11) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36021" pm="."><plain>Extra nodal growth </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36022" pm="."><plain>No or pN0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36023" pm="."><plain>154 (73) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36024" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36025" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36026" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36027" pm="."><plain>56 (26) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36028" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36029" pm="."><plain>2 (1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36030" pm="."><plain>Vaso‐invasion </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36031" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36032" pm="."><plain>169 (80) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36033" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36034" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36035" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36036" pm="."><plain>39 (18) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36037" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36038" pm="."><plain>4 (2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36039" pm="."><plain>Perineural growth </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36040" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36041" pm="."><plain>122 (58) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36042" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36043" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36044" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36045" pm="."><plain>80 (38) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36046" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36047" pm="."><plain>10 (4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36048" pm="."><plain>Bone invasion </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36049" pm="."><plain>No </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36050" pm="."><plain>152 (72) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36051" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36052" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36053" pm="."><plain>Yes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36054" pm="."><plain>60 (28) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36055" pm="."><plain>Growth pattern </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36056" pm="."><plain>Cohesive </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36057" pm="."><plain>44 (20.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36058" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36059" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36060" pm="."><plain>Noncohesive </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36061" pm="."><plain>167 (79) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36062" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36063" pm="."><plain>1 (0.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36064" pm="."><plain>Infiltration depth </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36065" pm="."><plain>0–4 mm </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36066" pm="."><plain>19 (9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36067" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36068" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36069" pm="."><plain>&gt;4 mm </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36070" pm="."><plain>193 (91) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36071" pm="."><plain>Differentiation grade </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36072" pm="."><plain>Well/moderate </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36073" pm="."><plain>173 (82) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36074" pm="."><plain>NA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36075" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36076" pm="."><plain>Poor/undifferentiated </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36077" pm="."><plain>39 (18) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="36078" pm="."><plain>HPV‐16 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36079" pm="."><plain>Positive </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36080" pm="."><plain>2 (1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36081" pm="."><plain>43 (18) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36082" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36083" pm="."><plain>Negative </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36084" pm="."><plain>210 (99) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36085" pm="."><plain>188 (78) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"><text><SENT sid="36086" pm="."><plain>Missing </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36087" pm="."><plain>0 (0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="36088" pm="."><plain>9 (4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cam4595-note-0002"><p><text><SENT sid="36089" pm="."><plain>OSCC, oral squamous cell carcinoma; OPSCC, oropharyngeal squamous cell carcinoma. </plain></SENT>
</text></p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></SecTag></sec><sec id="cam4595-sec-0011"><title><text><SENT sid="36090" pm="."><plain>FGFR3 protein is frequently overexpressed in oral and oropharyngeal squamous cell carcinoma </plain></SENT>
</text></title><p><text><SENT sid="36091" pm="."><plain>Representative microscopic images of FGFR3 protein expression are shown in Figure  1. </plain></SENT>
<SENT sid="36092" pm="."><plain>A subset of OSCC and OPSCC showed more intense staining and a subset showed lighter staining compared to the faint staining observed in normal oral and tonsillar tissue. </plain></SENT>
<SENT sid="36093" pm="."><plain>Specifically, FGFR3 protein was overexpressed in 48% (89/185) of OSCC and 59% (124/211) of OPSCC (Fig. 2A, Table 1). </plain></SENT>
<SENT sid="36094" pm="."><plain>FGFR3 protein expression was unknown for 27 OSCC and 29 OPSCC because all three TMA cores of the tumor were missing. </plain></SENT>
<SENT sid="36095" pm="."><plain>Overexpression of FGFR3 protein occurred significantly more in OPSCC (P = 0.034). </plain></SENT>
<SENT sid="36096" pm="."><plain>Regarding the OPSCC population, there was no significant difference in FGFR3 protein expression between HPV‐positive and ‐negative OPSCC (P = 0.489). </plain></SENT>
<SENT sid="36097" pm="."><plain>To investigate the underlying mechanism of FGFR3 protein overexpression in OSCC and OPSCC, FGFR3 mRNA data of 522 HNSCC were retrieved from The Cancer Genome Atlas (TCGA) Research Network. </plain></SENT>
<SENT sid="36098" pm="."><plain>FGFR3 mRNA levels were upregulated in 3% (18/522) of HNSCC and normal in the rest of the HNSCC cohort (Fig. 2B). </plain></SENT>
<SENT sid="36099" pm="."><plain>None of them showed downregulated FGFR3 mRNA levels. </plain></SENT>
<SENT sid="36100" pm="."><plain>In the OSCC and OPSCC cohort, the FGFR3 gene was gained in only 0.6% (1/179) of OSCC, but not truly amplified in OSCC nor OPSCC (Fig. 1, Table S1). </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="cam4595-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="36101" pm="."><plain>Microscopic images of immunohistochemical staining for FGFR3 protein at 10× and 40× magnification and fluorescence in situ hybridization of the FGFR3 gene at 100× magnification. </plain></SENT>
<SENT sid="36102" pm="."><plain>Tissue microarray slides containing oral and oropharyngeal squamous cell carcinoma cores (0.6 mm) were immunohistochemically stained for FGFR3 protein using an anti‐FGFR3 antibody. </plain></SENT>
<SENT sid="36103" pm="."><plain>Fluorescence in situ hybridization of the FGFR3 gene was performed on another set of tissue microarray slides. </plain></SENT>
<SENT sid="36104" pm="."><plain>Strong immunohistochemical staining was observed in (A) oral squamous cell carcinoma and (B) oropharyngeal squamous cell carcinoma overexpressing FGFR3 protein. </plain></SENT>
<SENT sid="36105" pm="."><plain>No staining was observed in (C) oral squamous cell carcinoma and (D) oropharyngeal squamous cell carcinoma not expressing FGFR3 protein. </plain></SENT>
<SENT sid="36106" pm="."><plain>Normal tonsillar tissue (E) showed no staining for FGFR3 protein. </plain></SENT>
<SENT sid="36107" pm="."><plain>(F) FGFR3 copy‐number gain and (G) normal FGFR3 gene copy‐numbers in oral squamous cell carcinoma. </plain></SENT>
<SENT sid="36108" pm="."><plain>The red probe signal is hybridized to the FGFR3 gene and the green probe signal is hybridized to the IGH gene. FGFR3, fibroblast growth factor receptor 3; OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral squamous cell carcinoma; IGH, immunoglobulin heavy locus. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-3" xlink:href="CAM4-5-275-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="cam4595-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="36109" pm="."><plain>Prevalence of FGFR3 protein overexpression and FGFR3 mRNA levels in head and neck squamous cell carcinoma. </plain></SENT>
<SENT sid="36110" pm="."><plain>(A) Tissue microarray slides containing oral and oropharyngeal squamous cell carcinoma cores (0.6 mm) were immunohistochemically stained for FGFR3 protein using an anti‐FGFR3 antibody. FGFR3 protein was overexpressed in 48% (89/185) of oral squamous cell carcinoma and 59% (124/211) of oropharyngeal squamous cell carcinoma. </plain></SENT>
<SENT sid="36111" pm="."><plain>Within the oropharyngeal population, FGFR3 protein was overexpressed in 53% (20/38) of HPV‐positive and 59% (97/165) of HPV‐negative oropharyngeal squamous cell carcinoma. </plain></SENT>
<SENT sid="36112" pm="."><plain>(B) Data on FGFR3 mRNA levels of 522 HNSCC were retrieved from The Cancer Genome Atlas (TCGA) Research Network on the 29th of September, 2015. FGFR3 mRNA levels were upregulated in 3% (18/522) of all HNSCC and normal in all other HNSCC head and neck squamous cell carcinoma. FGFR3, fibroblast growth factor receptor 3; HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma; OSCC, oral squamous cell carcinoma. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-5" xlink:href="CAM4-5-275-g002"/></fig></sec><sec id="cam4595-sec-0012"><title><text><SENT sid="36113" pm="."><plain>FGFR3 protein expression is not related to overall survival or disease‐free survival in oral and oropharyngeal squamous cell carcinoma </plain></SENT>
</text></title><p><text><SENT sid="36114" pm="."><plain>Expression of FGFR3 protein was not related to overall survival or disease‐free survival in OSCC patients (HR [hazard ratio]: 0.94; 95% CI: 0.64–1.39; P = 0.769, HR: 0.94; 95% CI: 0.65–1.36; P = 0.750). </plain></SENT>
<SENT sid="36115" pm="."><plain>Also not in OPSCC patients (HR: 1.21; 95% CI: 0.81–1.80; P = 0.361, HR: 0.42; 95% CI: 0.79–1.77; P = 0.419) (Fig. 3, Fig. </plain></SENT>
<SENT sid="36116" pm="."><plain>S1). </plain></SENT>
<SENT sid="36117" pm="."><plain>Furthermore, FGFR3 protein expression was not related to overall survival or disease‐free survival in subgroups of HPV‐positive OPSCC (HR [hazard ratio]: 0.74; 95% CI: 0.20–2.77; P = 0.657, HR: 0.48; 95% CI: 0.14–1.64; P = 0.241) and HPV‐negative OPSCC patients (HR: 1.28; 95% CI: 0.84–1.97; P = 0.249, HR: 1.40; 95% CI: 0.90–2.16; P = 0.133). </plain></SENT>
<SENT sid="36118" pm="."><plain>Fibroblast growth factor receptor 3 (FGFR3) protein expression showed no relevant relationship with clinicopathological variables, including differentiation grade, tumor stage, and regional lymph node metastases. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="cam4595-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="36119" pm="."><plain>Kaplan–Meier overall survival curves for FGFR3 protein expression in oral and oropharyngeal squamous cell carcinoma. </plain></SENT>
<SENT sid="36120" pm="."><plain>Tissue microarray slides containing cores (0.6 mm) of 212 oral and 240 oropharyngeal squamous cell carcinoma were immunohistochemically stained for FGFR3 protein using an anti‐FGFR3 antibody. FGFR3 protein expression was not related to overall survival in (A) oral squamous cell carcinoma (HR: 0.94; 95% CI: 0.64–1.39; P = 0.769) and (B) oropharyngeal squamous cell carcinoma (HR: 1.21; 95% CI: 0.81–1.80; P = 0.361). </plain></SENT>
<SENT sid="36121" pm="."><plain>Similarly, FGFR3 protein expression was not related to overall survival in (C) HPV‐positive (HR: 0.74; 95% CI: 0.20–2.77; P = 0.657) and (D) HPV‐negative oropharyngeal squamous cell carcinoma (HR: 1.28; 95% CI: 0.84–1.97; P = 0.249). FGFR3, fibroblast growth factor receptor 3; HPV, human papillomavirus; HR, hazard ratio. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-7" xlink:href="CAM4-5-275-g003"/></fig></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="cam4595-sec-0013"><title><text><SENT sid="36122" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="36123" pm="."><plain>In this study, FGFR3 protein appeared to be frequently overexpressed in both OSCC and OPSCC, and FGFR3 mRNA was found to be upregulated in HNSCC from the TCGA Research Network. </plain></SENT>
<SENT sid="36124" pm="."><plain>Upregulated FGFR3 mRNA levels may account for the overexpression of FGFR3 protein in a minor subset of FGFR3‐overexpressed OSCC and OPSCC samples. </plain></SENT>
<SENT sid="36125" pm="."><plain>However, for the majority of FGFR3‐overexpressed samples, the mechanism of overexpression remains unknown. </plain></SENT>
<SENT sid="36126" pm="."><plain>Similar overexpression of FGFR3 protein has been observed in a previous study. </plain></SENT>
<SENT sid="36127" pm="."><plain>They observed FGFR3 protein overexpression in 13 of 14 OSCC cell lines and in five OSCC tissues 16. </plain></SENT>
<SENT sid="36128" pm="."><plain>Their method was Quantitative Reverse Transcription Polymerase Chain Reaction (QRT‐PCR), whereas immunohistochemistry was used in this study. </plain></SENT>
<SENT sid="36129" pm="."><plain>Since no consensus on a cut‐off value has been reached yet, we selected an arbitrary cut‐off value to define protein overexpression by immunohistochemistry. </plain></SENT>
<SENT sid="36130" pm="."><plain>Fibroblast growth factor receptor 3 (FGFR3) protein has become an interesting therapeutic target as several FGFR inhibitor therapies have become available. </plain></SENT>
<SENT sid="36131" pm="."><plain>These FGFR inhibitors show promising therapeutic value for treating HNSCC in in vitro and in vivo experiments. </plain></SENT>
<SENT sid="36132" pm="."><plain>For example, targeting FGFR3 with FGFR‐inhibitor PD173074 reduced cell proliferation and enhanced radiotherapy sensitivity of resistant OSCC cell lines and xenografts 17. </plain></SENT>
<SENT sid="36133" pm="."><plain>Hence, targeting FGFR3 could be of interest for radiotherapy treatment strategies in radiotherapy resistant OSCC patients. </plain></SENT>
</text></p><p><text><SENT sid="36134" pm="."><plain>Regarding other types of cancer, the overexpression of FGFR3 protein has been observed in a wide spectrum of solid tumors including transitional cell, hepatocellular, and breast carcinoma, as well as multiple myeloma 18, 19, 20, 21, 22, 23, 24. </plain></SENT>
<SENT sid="36135" pm="."><plain>Similar overexpression of FGFR3 protein was observed in this study. </plain></SENT>
<SENT sid="36136" pm="."><plain>Though, the contribution of FGFR3 protein overexpression to tumor progression seems to be tumor‐type dependent. </plain></SENT>
<SENT sid="36137" pm="."><plain>FGFR3 protein overexpression drives tumor progression in bladder cancer, lung cancer, multiple myeloma, and glioblastoma, whereas it prevents tumor progression in cutaneous squamous cell carcinoma 25, 26. </plain></SENT>
<SENT sid="36138" pm="."><plain>In HNSCC, FGFR3 protein overexpression seems to drive tumor progression, as reported by Uzawa et al. 17. </plain></SENT>
</text></p><p><text><SENT sid="36139" pm="."><plain>We found FGFR3 protein expression to be of no prognostic value in OSCC as well as in OPSCC. </plain></SENT>
<SENT sid="36140" pm="."><plain>The prognostic value of FGFR3 protein expression has not been evaluated before 27. </plain></SENT>
<SENT sid="36141" pm="."><plain>This holds both true for HPV‐negative and HPV‐positive tumors despite their different mechanism of FGFR3 activation. </plain></SENT>
<SENT sid="36142" pm="."><plain>The prognostic value of FGFR3 protein expression seems to be tumor‐type dependent. </plain></SENT>
<SENT sid="36143" pm="."><plain>Similar to this HNSCC study, FGFR3 protein expression holds no prognostic value in non‐small cell lung cancer 28. </plain></SENT>
<SENT sid="36144" pm="."><plain>This is in contrast to multiple myeloma and breast cancer, in which FGFR3 protein expression has been related to poor progression‐free survival and overall survival 23, 24. </plain></SENT>
<SENT sid="36145" pm="."><plain>For transitional cell carcinoma, the prognostic value for FGFR3 expression is still a subject of debate 18, 19, 29, 30, 31, 32, 33, 34. </plain></SENT>
</text></p><p><text><SENT sid="36146" pm="."><plain>Previous large‐scale genomic characterization studies show that the FGFR3 gene is frequently aberrant in HPV‐positive HNSCC (11%) and much less in HPV‐negative HNSCC (2%) 35, 36. </plain></SENT>
<SENT sid="36147" pm="."><plain>Specifically, FGFR3‐TACC3 translocations occur predominantly in HPV‐positive HNSCC, whereas FGFR3 amplification occurs in HPV‐negative HNSCC and FGFR3 mutations occur in both. </plain></SENT>
<SENT sid="36148" pm="."><plain>Tumors bearing these FGFR3 gene aberrations respond very well to FGFR‐inhibitors in preclinical models and early phase clinical studies 37. </plain></SENT>
<SENT sid="36149" pm="."><plain>Considering the frequent occurrence of FGFR3 aberrations in HPV‐positive HNSCC and impressive response to FGFR‐inhibitors, FGFR3 protein might be of therapeutic value in this HNSCC subpopulation. </plain></SENT>
<SENT sid="36150" pm="."><plain>Clinical studies are currently focusing on this HPV‐positive subpopulation 37. </plain></SENT>
<SENT sid="36151" pm="."><plain>The FGFR3 amplification observed by the previous study in a mixed HPV‐negative HNSCC cohort was not observed in the OSCC and OPSCC cohorts in this study 30. </plain></SENT>
<SENT sid="36152" pm="."><plain>An explanation could be that the FGFR3 gene is amplified in HNSCC tumors other than OSCC and OPSCC or gene amplification is not detected by our FISH analysis due to the arbitrarily selected ratio and cut‐off values. </plain></SENT>
<SENT sid="36153" pm="."><plain>In the OSCC and OPSCC of this study, other mechanisms than FGFR3 gene amplification are probably responsible for FGFR3 protein overexpression. </plain></SENT>
</text></p><p><text><SENT sid="36154" pm="."><plain>In conclusion, FGFR3 protein is frequently overexpressed in both OSCC and OPSCC. </plain></SENT>
<SENT sid="36155" pm="."><plain>Although FGFR3 protein expression is not related to overall survival or disease‐free survival, previous studies found a high occurrence rate of FGFR3 genomic aberrations in HNSCC. </plain></SENT>
<SENT sid="36156" pm="."><plain>Therefore, FGFR3 protein may be an interesting therapeutic target for FGFR3‐directed therapies in OSCC and OPSCC. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec id="cam4595-sec-0014"><title><text><SENT sid="36157" pm="."><plain>Conflict of Interest </plain></SENT>
</text></title><p><text><SENT sid="36158" pm="."><plain>All authors had no conflicts of interest to declare. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="36159" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data"><caption><p><text><SENT sid="36160" pm="."><plain>Figure S1. Kaplan–Meier disease‐free survival curves for FGFR3 protein expression in oral and oropharyngeal squamous cell carcinoma. </plain></SENT>
</text></p></caption><media xlink:href="CAM4-5-275-s001.tif"><caption><p><text><SENT sid="36161" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p><text><SENT sid="36162" pm="."><plain>Table S1. </plain></SENT>
<SENT sid="36163" pm="."><plain>FGFR3 protein expression and FGFR3 gene copy‐numbers in oral and oropharyngeal squamous cell carcinoma. </plain></SENT>
</text></p></caption><media xlink:href="CAM4-5-275-s002.docx"><caption><p><text><SENT sid="36164" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="REF"><ref-list content-type="cited-references" id="cam4595-bibl-0001"><title>References</title><ref id="cam4595-bib-0001"><text><SENT sid="36165" pm="."><plain>1  Brooks, A. N. ,  E. Kilgour , and  P. D. Smith . 2012 Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin. </plain></SENT>
<SENT sid="36168" pm="."><plain>Cancer Res. 18:1855–1862.22388515 </plain></SENT>
</text></ref><ref id="cam4595-bib-0002"><text><SENT sid="36169" pm="."><plain>2  L'Hôte, C. G. , and  M. A. Knowles . 2005 Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. </plain></SENT>
<SENT sid="36172" pm="."><plain>Cell Res. 304:417–431.15748888 </plain></SENT>
</text></ref><ref id="cam4595-bib-0003"><text><SENT sid="36173" pm="."><plain>3  Daniele, G. ,  J. Corral ,  L. R. Molife , and  J. S. de Bono . 2012 FGF receptor inhibitors: role in cancer therapy. Curr. </plain></SENT>
<SENT sid="36176" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="36177" pm="."><plain>Rep. 14:111–119.22311684 </plain></SENT>
</text></ref><ref id="cam4595-bib-0004"><text><SENT sid="36178" pm="."><plain>4  Dienstmann, R. ,  J. Rodon ,  A. Prat ,  J. Perez‐Garcia ,  B. Adamo ,  E. Felip , et al. 2014 Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. </plain></SENT>
<SENT sid="36179" pm="."><plain>Oncol. 25:552–563.24265351 </plain></SENT>
</text></ref><ref id="cam4595-bib-0005"><text><SENT sid="36180" pm="."><plain>5  Dieci, M. V. ,  M. Arnedos ,  F. Andre , and  J. C. Soria . 2013 Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 3:264–279.23418312 </plain></SENT>
</text></ref><ref id="cam4595-bib-0006"><text><SENT sid="36183" pm="."><plain>6  Di Stefano, A. L. ,  A. Fucci ,  V. Frattini ,  M. Labussiere ,  K. Mokhtari ,  P. Zoppoli , et al. 2015 Detection, characterization and inhibition of FGFR‐TACC fusions in IDH wild type glioma. Clin. </plain></SENT>
<SENT sid="36185" pm="."><plain>Cancer Res. 21:3307–3317.25609060 </plain></SENT>
</text></ref><ref id="cam4595-bib-0007"><text><SENT sid="36186" pm="."><plain>7  Pulte, D. , and  H. Brenner . 2010 Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 15:994–1001.20798198 </plain></SENT>
</text></ref><ref id="cam4595-bib-0008"><text><SENT sid="36187" pm="."><plain>8  Kang, H. ,  A. Kiess , and  C. H. Chung . 2015 Emerging biomarkers in head and neck cancer in the era of genomics. Nat. </plain></SENT>
<SENT sid="36189" pm="."><plain>Rev. </plain></SENT>
<SENT sid="36190" pm="."><plain>Clin. </plain></SENT>
<SENT sid="36191" pm="."><plain>Oncol. 12:11–26.25403939 </plain></SENT>
</text></ref><ref id="cam4595-bib-0009"><text><SENT sid="36192" pm="."><plain>9 Nederlandse Vereniging voor KNO 2014 Richtlijn hoofd‐halstumoren.Utrecht  </plain></SENT>
</text></ref><ref id="cam4595-bib-0010"><text><SENT sid="36193" pm="."><plain>10  van Kempen, P. M. ,  L. van Bockel ,  W. W. Braunius ,  C. B. Moelans ,  M. van Olst ,  R. de Jong , et al. 2014 HPV‐positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation. Cancer Med. 3:1185–1196.25065733 </plain></SENT>
</text></ref><ref id="cam4595-bib-0011"><text><SENT sid="36196" pm="."><plain>11  Hughes, S. E.  1997 Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. </plain></SENT>
<SENT sid="36199" pm="."><plain>Cytochem. 45:1005–1019.9212826 </plain></SENT>
</text></ref><ref id="cam4595-bib-0012"><text><SENT sid="36200" pm="."><plain>12  Williams, B. ,  J. N. Mandrekar ,  S. J. Mandrekar ,  S. S. Cha , and  A. F. Furth . 2006 Finding optimal cutpoints for continuous covariates with binary and time‐to‐Event outcomes. Mayo Foundation, Rochester. </plain></SENT>
</text></ref><ref id="cam4595-bib-0013"><text><SENT sid="36204" pm="."><plain>13  Schildhaus, H. U. ,  L. C. Heukamp ,  S. Merkelbach‐Bruse ,  K. Riesner ,  K. Schmitz ,  E. Binot , et al. 2012 Definition of a fluorescence in‐situ hybridization score identifies high‐ and low‐level FGFR1 amplification types in squamous cell lung cancer. Mod. </plain></SENT>
<SENT sid="36207" pm="."><plain>Pathol. 25:1473–1480.22684217 </plain></SENT>
</text></ref><ref id="cam4595-bib-0014"><text><SENT sid="36208" pm="."><plain>14  Gao, J. ,  B. A. Aksoy ,  U. Dogrusoz ,  G. Dresdner ,  B. Gross ,  S. O. Sumer , et al. 2013 Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. </plain></SENT>
<SENT sid="36211" pm="."><plain>Signal. 6:p11. </plain></SENT>
</text></ref><ref id="cam4595-bib-0015"><text><SENT sid="36212" pm="."><plain>15  Cerami, E. ,  J. Gao ,  U. Dogrusoz ,  B. E. Gross ,  S. O. Sumer ,  B. A. Aksoy , et al. 2012 The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404.22588877 </plain></SENT>
</text></ref><ref id="cam4595-bib-0016"><text><SENT sid="36215" pm="."><plain>16  Henson, B. J. , and  S. M. Gollin . 2010 Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenet. </plain></SENT>
<SENT sid="36218" pm="."><plain>Genome Res. 128:192–198.20539070 </plain></SENT>
</text></ref><ref id="cam4595-bib-0017"><text><SENT sid="36219" pm="."><plain>17  Uzawa, K. ,  T. Ishigami ,  K. Fushimi ,  T. Kawata ,  K. Shinozuka ,  A. Kasamatsu , et al. 2011 Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells. Oncogene 30:4447–4452.21577207 </plain></SENT>
</text></ref><ref id="cam4595-bib-0018"><text><SENT sid="36220" pm="."><plain>18  Turo, R. ,  P. Harnden ,  H. Thygesen ,  A. Fleischmann ,  G. N. Thalmann ,  R. Seiler , et al. 2015 FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases. J. Urol. 193:325–s330.24933362 </plain></SENT>
</text></ref><ref id="cam4595-bib-0019"><text><SENT sid="36222" pm="."><plain>19  Guancial, E. A. ,  L. Werner ,  J. Bellmunt ,  A. Bamias ,  T. K. Choueiri ,  R. Ross , et al. 2014 FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 3:835–844.24846059 </plain></SENT>
</text></ref><ref id="cam4595-bib-0020"><text><SENT sid="36224" pm="."><plain>20  Gómez‐Román, J. J. ,  P. Saenz ,  M. Molina ,  J. Cuevas González ,  K. Escuredo ,  S. Santa Cruz , et al. 2005 Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin. </plain></SENT>
<SENT sid="36226" pm="."><plain>Cancer Res. 11:459–465.15701828 </plain></SENT>
</text></ref><ref id="cam4595-bib-0021"><text><SENT sid="36227" pm="."><plain>21  Tomlinson, D. C. ,  O. Baldo ,  P. Harnden , and  M. A. Knowles . 2007 FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213:91–98.17668422 </plain></SENT>
</text></ref><ref id="cam4595-bib-0022"><text><SENT sid="36231" pm="."><plain>22  Qiu, W. H. ,  B. S. Zhou ,  P. G. Chu ,  W. G. Chen ,  C. Chung ,  J. Shih , et al. 2005 Over‐expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J. Gastroenterol. 11:5266–5272.16149130 </plain></SENT>
</text></ref><ref id="cam4595-bib-0023"><text><SENT sid="36237" pm="."><plain>23  Kuroso, K. ,  Y. Imai ,  M. Kobayashi ,  K. Yanagimoto ,  T. Suzuki ,  M. Kojima , et al. 2010 Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology 77:231–240.21116113 </plain></SENT>
</text></ref><ref id="cam4595-bib-0024"><text><SENT sid="36238" pm="."><plain>24  Chang, H. ,  A. K. Stewart ,  X. Y. Qi ,  Z. H. Li ,  Q. L. Yi , and  S. Trudel . 2005 Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106:353–355.15761022 </plain></SENT>
</text></ref><ref id="cam4595-bib-0025"><text><SENT sid="36243" pm="."><plain>25  Mandinova, A. ,  V. Kolev ,  V. Neel ,  B. Hu ,  W. Stonely ,  J. Lieb , et al. 2009 A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J. Clin. </plain></SENT>
<SENT sid="36245" pm="."><plain>Invest. 119:3127–3137.19729838 </plain></SENT>
</text></ref><ref id="cam4595-bib-0026"><text><SENT sid="36246" pm="."><plain>26  Duperret, E. K. ,  S. J. Oh ,  A. McNeal ,  S. M. Prouty , and  T. W. Ridky . 2014 Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors. Cell Cycle 13:1551–1559.24626198 </plain></SENT>
</text></ref><ref id="cam4595-bib-0027"><text><SENT sid="36251" pm="."><plain>27  Ipenburg, N. A. ,  K. Koole ,  K. S. Liem ,  P. M. van Kempen ,  R. Koole ,  P. J. van Diest , et al. 2015 Fibroblast growth factor receptor family members as prognostic biomarkers in head and neck squamous cell carcinoma. Target. </plain></SENT>
<SENT sid="36256" pm="."><plain>Oncol. doi:<ext-link ext-link-type="doi" xlink:href="10.1007/s11523-015-0374-9">10.1007/s11523‐015‐0374‐9</ext-link>. </plain></SENT>
</text></ref><ref id="cam4595-bib-0028"><text><SENT sid="36257" pm="."><plain>28  Woenckhaus, M. ,  J. Merk ,  R. Stoehr ,  F. Schaeper ,  A. Gaumann ,  K. Wiebe , et al. 2008 Prognostic value of FHIT, CTNNB1, and MUC1 expression in non‐small cell lung cancer. Hum. </plain></SENT>
<SENT sid="36258" pm="."><plain>Pathol. 39:126–136.17949785 </plain></SENT>
</text></ref><ref id="cam4595-bib-0029"><text><SENT sid="36259" pm="."><plain>29  Mhawech‐Fauceglia, P. ,  R. T. Cheney ,  G. Fischer ,  A. Beck , and  F. R. Herrmann . 2006 FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur. </plain></SENT>
<SENT sid="36262" pm="."><plain>J. </plain></SENT>
<SENT sid="36263" pm="."><plain>Surg. </plain></SENT>
<SENT sid="36264" pm="."><plain>Oncol. 32:231–237.16412606 </plain></SENT>
</text></ref><ref id="cam4595-bib-0030"><text><SENT sid="36265" pm="."><plain>30  Maeng, Y. H. ,  S. Y. Eun , and  J. S. Huh . 2010 Expression of fibroblast growth factor receptor 3 in the recurrence of non‐muscle‐invasive urothelial carcinoma of the bladder. Korean J. Urol. 51:94–100.20414420 </plain></SENT>
</text></ref><ref id="cam4595-bib-0031"><text><SENT sid="36270" pm="."><plain>31  Bodoor, K. ,  A. Ghabkari ,  Z. Jaradat ,  A. Alkhateeb ,  S. Jaradat ,  M. A. Al‐Ghazo , et al. 2010 FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 34:724–732.20542753 </plain></SENT>
</text></ref><ref id="cam4595-bib-0032"><text><SENT sid="36272" pm="."><plain>32  van Rhijn, B. W. ,  L. Liu ,  A. N. Vis ,  P. J. Bostrom ,  T. C. Zuiverloon ,  N. E. Fleshner , et al. 2012 Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int. 110:1169–1176.22448597 </plain></SENT>
</text></ref><ref id="cam4595-bib-0033"><text><SENT sid="36278" pm="."><plain>33  Sung, J. Y. ,  J. M. Sun ,  B. Chang Jeong ,  S. Il Seo ,  S. Soo Jeon ,  H. Moo Lee , et al. 2014 FGFR3 overexpression is prognostic of adverse outcome for muscle‐invasive bladder carcinoma treated with adjuvant chemotherapy. Urol. </plain></SENT>
<SENT sid="36281" pm="."><plain>Oncol. 32:49.e23–49.e31.24360661 </plain></SENT>
</text></ref><ref id="cam4595-bib-0034"><text><SENT sid="36282" pm="."><plain>34  Bertz, S. ,  C. Abeé ,  S. Schwarz‐Furlan ,  J. Alfer ,  F. Hofstädter ,  R. Stoehr , et al. 2014 Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer. Virchows Arch. 465:687–695.25326864 </plain></SENT>
</text></ref><ref id="cam4595-bib-0035"><text><SENT sid="36283" pm="."><plain>35 Cancer Genome Atlas Network 2015 Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582.25631445 </plain></SENT>
</text></ref><ref id="cam4595-bib-0036"><text><SENT sid="36284" pm="."><plain>36  Seiwert, T. Y. ,  Z. Zuo ,  M. K. Keck ,  A. Khattri ,  C. S. Pedamallu ,  T. Stricker , et al. 2015 Integrative and comparative genomic analysis of HPV‐positive and HPV‐negative head and neck squamous cell carcinomas. Clin. </plain></SENT>
<SENT sid="36288" pm="."><plain>Cancer Res. 21:632–641.25056374 </plain></SENT>
</text></ref><ref id="cam4595-bib-0037"><text><SENT sid="36289" pm="."><plain>37  Hammerman, P. S. ,  D. N. Hayes , and  J. R. Grandis . 2015 Therapeutic insights from genomic studies of head and Neck squamous cell carcinomas. Cancer Discov. 5:239–245.25643909 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
